Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Recruiting 3Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1

Conditions

Multiple Myeloma 49Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Follicular 14Lymphoma, B-Cell, Marginal Zone 13Lymphoma 9Recurrence 7Lymphoma, Non-Hodgkin 7Neoplasms 6Lymphoma, Mantle-Cell 5Lymphoma, B-Cell 4Neoplasms, Plasma Cell 3Neoplasm, Residual 3Lymphoma, T-Cell, Peripheral 3Smoldering Multiple Myeloma 2Leukemia, Plasma Cell 2Hematologic Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Vitamin D Deficiency 1Peripheral Nervous System Diseases 1Paraproteinemias 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Diseases 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Corneal Diseases 1Cardiotoxicity 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 7venetoclax 6Azacitidine 6fludarabine 5Cytarabine 4Blood Specimen Collection 4daratumumab 3Lenalidomide 3Daunorubicin 3tislelizumab 2fludarabine phosphate 2blinatumomab 2Rituximab 2Liquid Biopsy 2Idarubicin 2Gemtuzumab 2Capecitabine 2Busulfan 2trastuzumab deruxtecan 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1tagraxofusp 1sugemalimab 1sacituzumab govitecan 1relugolix 1pembrolizumab 1pegaspargase 1palbociclib 1obinutuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Neoplasm, Residual × Lenalidomide × Clear all
NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

University of Alabama at Birmingham

Phase 2 Recruiting
40 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT06414148 2025-06-05

EpLCART

Peter MacCallum Cancer Centre, Australia

Phase 2 Recruiting
40 enrolled
Lymphoid

Lymphoma, Recurrence, Neoplasm, Residual

NCT06697483 2024-11-25

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Peking University People's Hospital

Phase NA Recruiting
100 enrolled
Plasma cell

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡